KRAS Exon 2 Mutation

CI-VAR-00001006Explore in graph →CIViC 75

Curated evidence

Evidence by cancer (12 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–12 of 12 evidence items across 5 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Colon Carcinoma1
KRAS Exon 2 Mutation AND MSI Low	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID12073 5577 colon carcinoma tumors were evaluated for BRAF, KRAS, and mismatch repair status. From those successfully evaluated, 201 had microsatellite instability (MSI or MSI-H) and BRAF V600E, 72 had MSI a… (full text at CIViC) PMID 28040692 · Taieb et al., 2017 · Open in CIViC	civic
Malignant Colorectal Neoplasm7
KRAS Exon 2 Mutation	(prognostic)	Prognostic	B	Does Not Support Poor Outcome	3	accepted	EID2361 This retrospective study examines outcomes of 158 primary sporadic colorectal cancer patients who had undergone surgical resection and were treated with 5-fluorouracil based chemotherapy. KRAS exon 2 … (full text at CIViC) PMID 17590872 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Pancreatic Neoplasm1
KRAS Exon 2 Mutation	Erlotinib + GemcitabineCombination	Predictive	B	Supports Resistance	4	accepted	EID1219 In a retrospective study of 136 pancreatic cancer patients, point mutations in KRAS exon 2 were associated with worse overall survival compared to that of wild-type KRAS (5.8 vs 8.0 months; P = 0.001;… (full text at CIViC) PMID 21862683 · Kim et al., 2011 · Open in CIViC	civic

Pancreatic Carcinoma2
KRAS Exon 2 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID917 KRAS exon 2 was mutated in 121 of 173 patients with advanced pancreatic cancer. Patients with KRAS wildtype had an improved OS (HR 1.68, p = 0.005). PMID 23435671 · Boeck et al., 2013 · Open in CIViC	civic
KRAS Exon 2 Mutation	Erlotinib	Predictive	B	Does Not Support Resistance	3	accepted	EID916 KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment. PMID 23435671 · Boeck et al., 2013 · Open in CIViC	civic

Rectal Carcinoma1
KRAS Exon 2 Mutation	(prognostic)	Prognostic	B	Does Not Support Poor Outcome	2	accepted	EID4052 This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for KRAS exon 2 mutations (l… (full text at CIViC) PMID 19903786 · He et al., 2009 · Open in CIViC	civic